Search clinical trials for: BRAF Mutation-Related Tumors

Total 16101 results

Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Melanoma and Brain Metastases

Canada, United States, Australia, France, Germany, Italy, Spain
MedImmune LLC

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma

Italy, United States, Canada, France
University Health Network, Toronto

Completed

Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma

Melanoma

Canada
Hoffmann-La Roche

Completed

Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors

Solid Tumors

United States
Novartis Pharmaceuticals

Completed

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Cancer

United States, Canada, Australia, France, Germany, Poland, Spain, United Kingdom, Italy
Manisha Shah
National Comprehensive Cancer Network

Completed

Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
GlaxoSmithKline

Terminated

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Melanoma

Spain, France
Duke University

Withdrawn

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma

Melanoma

United States
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (MELANIS)

Melanoma

France
The Netherlands Cancer Institute

Unknown

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Melanoma | Skin Neoplasms

Netherlands
Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
GlaxoSmithKline

Terminated

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Melanoma and Brain Metastases

United States, Australia
National Cancer Institute (NCI)
Glaxosmithkline Biologicals S.A.

Terminated

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Renal Failure | Solid Neoplasm | BRAF Gene Mutation | Hepatic Complication

United States, Canada
Bristol-Myers Squibb

Completed

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Melanoma

United States
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
Poitiers University Hospital

Completed

Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK (SVALMEL)

Unresecable Stage IIIc or IV Melanoma

France
GlaxoSmithKline
Pfizer

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Cancer

United States
Cascadian Therapeutics Inc.

Terminated

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Advanced BRAF-mutant Cancers

United States
University of Texas Southwestern Medical Center

Completed

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Melanoma

United States
Centre Hospitalier Universitaire de Nice

Unknown

Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) (MALT)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV
GlaxoSmithKline

Completed

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Melanoma

United States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina
University of California, San Francisco
GlaxoSmithKline

Terminated

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

BRAFV600E Melanoma Patients

United States
GlaxoSmithKline

Completed

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

Cancer

Australia, United States, United Kingdom
Hoffmann-La Roche

Completed

Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

Malignant Melanoma, Cancer

Hungary
GlaxoSmithKline

Completed

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Solid Tumours

United States
GlaxoSmithKline

Completed

An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

United States
GlaxoSmithKline

Completed

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Cancer

Australia, United States
GlaxoSmithKline

Completed

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Cancer

Japan
GlaxoSmithKline

Completed

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Cancer

United States
GlaxoSmithKline

Completed

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

Australia, United States, United Kingdom
GlaxoSmithKline

Completed

Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Cancer

United States, Australia, United Kingdom
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
GlaxoSmithKline

Completed

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Cancer

Australia, Spain, United States, Germany, Poland, Italy, Canada, Ireland, Hungary, Russian Federation, Netherlands, France
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
GlaxoSmithKline

Completed

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

Melanoma

Australia, France, Germany, United States, Italy
Hospices Civils de Lyon

Unknown

Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies (PAIR)

Metastatic Melanoma

France
GlaxoSmithKline

No longer available

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Melanoma

France
Hoffmann-La Roche

Completed

A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors

Neoplasms

Australia, Spain, Denmark
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
Hoffmann-La Roche

Completed

An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma

Malignant Melanoma

Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
Genentech, Inc.

Terminated

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Malignant Melanoma

United States
University of Utah

Withdrawn

Radiation Use During Vemurafenib Treatment

Stage IV Melanoma | BRAFV600 Mutation

United States
British Columbia Cancer Agency
BC Cancer Foundation

Completed

The Oncopanel Pilot (TOP) Study

Gastrointestinal Stromal Tumors | Colorectal Cancer Metastatic | Advanced Melanoma | Advanced Non-Small Cell Lung Carcinoma | Patients With Diagnosed Malignancies Being Considered for Clinical Trials

Canada
Massachusetts General Hospital

Terminated

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Melanoma

United States
Massachusetts General Hospital

Terminated

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Melanoma

United States
Hoffmann-La Roche

Completed

A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies

Malignant Melanoma, Neoplasms

Korea, Republic of, Brazil, United States, Canada, Cyprus
Samsung Medical Center

Completed

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Refractory Solid Tumors

Korea, Republic of

3

Subscribe